A1M Pharma AB appointed Tobias Larsson Agervald as chief medical officer, effective Dec. 1.

Agervald is a senior medical director in Astellas Pharma Inc.'s Global Clinical Development in the Netherlands. He also co-founded the European Renal Association - European Dialysis and Transplantation Association's endorsed Working Group on Mineral and Bone Disorders.

Sweden-based A1M Pharma is developing ROSgard, based on the protein alpha-1-microglobulin, or A1M, to treat pre-eclampsia, a pregnancy complication characterized by high blood pressure and signs of damage to another organ, most often the liver and kidney, as well as acute kidney injury.